[{"address1": "230 Park Avenue", "address2": "Suite 3350", "city": "New York", "state": "NY", "zip": "10169", "country": "United States", "phone": "646 885 8505", "website": "https://www.ymabs.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Gad", "age": 53, "title": "Founder, Chief Business Officer & Vice Chairman", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 1047496, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bo  Kruse", "age": 51, "title": "Executive VP, Secretary, Treasurer & CFO", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": 685021, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan  Smith", "age": 52, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 710000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Rossi", "age": 52, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joris Wiel Jan Wilms", "age": 49, "title": "Senior VP & COO", "yearBorn": 1974, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Torben  Lund-Hansen M.Sc., Ph.D.", "age": 72, "title": "Senior VP & CTO", "yearBorn": 1951, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steen  Lisby M.D., M.Sc.", "age": 59, "title": "Senior VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 393985, "exercisedValue": 0, "unexercisedValue": 274400}, {"maxAge": 1, "name": "Dr. Vignesh  Rajah M.B.A., MBBS", "age": 58, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 406275, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1704067200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.75, "open": 9.82, "dayLow": 9.47, "dayHigh": 10.09, "regularMarketPreviousClose": 9.75, "regularMarketOpen": 9.82, "regularMarketDayLow": 9.47, "regularMarketDayHigh": 10.09, "beta": 0.645, "forwardPE": -13.366198, "volume": 197603, "regularMarketVolume": 197603, "averageVolume": 258780, "averageVolume10days": 538280, "averageDailyVolume10Day": 538280, "bidSize": 800, "askSize": 1400, "marketCap": 413968960, "fiftyTwoWeekLow": 2.7, "fiftyTwoWeekHigh": 10.95, "priceToSalesTrailing12Months": 4.455927, "fiftyDayAverage": 6.7948, "twoHundredDayAverage": 6.5165, "currency": "USD", "enterpriseValue": 329021152, "profitMargins": -0.20754999, "floatShares": 27318038, "sharesOutstanding": 43621600, "sharesShort": 2312983, "sharesShortPriorMonth": 2492617, "sharesShortPreviousMonthDate": 1701302400, "dateShortInterest": 1703808000, "sharesPercentSharesOut": 0.053000003, "heldPercentInsiders": 0.14192, "heldPercentInstitutions": 0.60765, "shortRatio": 10.43, "shortPercentOfFloat": 0.0637, "impliedSharesOutstanding": 43621600, "bookValue": 2.296, "priceToBook": 4.133275, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -19282000, "trailingEps": -0.45, "forwardEps": -0.71, "pegRatio": 0.16, "enterpriseToRevenue": 3.542, "enterpriseToEbitda": -18.565, "52WeekChange": 1.1428571, "SandP52WeekChange": 0.19902325, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "YMAB", "underlyingSymbol": "YMAB", "shortName": "Y-mAbs Therapeutics, Inc.", "longName": "Y-mAbs Therapeutics, Inc.", "firstTradeDateEpochUtc": 1537536600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ef4c7aed-ff51-3117-8a16-0b2c87e3c948", "messageBoardId": "finmb_378585331", "gmtOffSetMilliseconds": -18000000, "currentPrice": 9.49, "targetHighPrice": 22.0, "targetLowPrice": 5.0, "targetMeanPrice": 12.29, "targetMedianPrice": 11.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 86571000, "totalCashPerShare": 1.985, "ebitda": -17723000, "totalDebt": 1623000, "quickRatio": 4.834, "currentRatio": 5.266, "totalRevenue": 92903000, "debtToEquity": 1.621, "revenuePerShare": 2.128, "returnOnAssets": -0.08489, "returnOnEquity": -0.18536, "freeCashflow": -8912375, "operatingCashflow": -27857000, "revenueGrowth": 0.631, "grossMargins": 0.87732005, "ebitdaMargins": -0.19077, "operatingMargins": -0.37884998, "financialCurrency": "USD", "trailingPegRatio": null}]